Pioneering Neuroscience Company to Turbocharge Therapeutics Pipeline Beyond Non-Hallucinogenic Analogs of First-Gen Psychedelics to Advance Psychoplastogens in Novel Chemical Space BOSTON, Feb. 14, 2023 /PRNewswire/ — Delix Therapeutics (the “Company”), a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions…


Previous articleIsrael-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv
Next articlePT389 – The Art of Ecstasy: The 90’s British Club Scene and MDMA